1324 U.S. P.I

## UTILITY PATENT APPLICATION TRANSMITTAL

Approved for use through 10/31/2002. OMB 0651-00							
Attorney Docket No.		59210.000046					
First Inventor		Ruey J. YU					
Title	IMPROVED BIOAVAILABILITY AND						
	IMPROVED DELIVERY OF ALKALINE						
	PHARMACEUTICAL DRUGS						

(Only for new nonprovisional applications under 37 CFR 1.53(b))			PHARMACEUTICAL DRUGS					
			Express Mail Label No.					
APPLICATION ELEMENTS  See MPEP chapter 600 concerning utility patent application contents.			Commissioner for Patents ADDRESS TO: Box Patent Application Washington, DC 20231					
1.  Fee Transmittal Form (e.g., PTO/S)		7.	☐ CD-RON		n, DC 20231 uplicate, large table	<u> </u>		
(Submit an original and a duplicate for fee pro     Applicant claims small entity status     See 37 CFR 1.27.	cessing) G.		Compute Nucleotide ar (if applicable	er Program (Ap nd/or Amino A nd, all necessary	pendix) cid Sequence Subm	10		
3. Specification [Total Pages 50]  (preferred arrangement set forth below)  - Descriptive title of the invention  - Cross Reference to Related Applications (if applicable)  - Statement Regarding Fed sponsored R & D (if applicable)  - Reference to sequence listing, a table,			b. Specification Sequence Listing on:  i. □ CD-ROM or CD-R (2 copies; or  ii. □ paper  c. □ Statements verifying identity of above copies					
or a computer program listing a - Background of the Invention		ACCOMPANYING APPLICATION PARTS						
- Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure  4. □ Drawing(s) (35 U.S.C. 113) [ Total Sheets ]  5. Oath or Declaration (unexecuted) [ Total Pages 03] a. □ Newly executed (original or copy) b. □ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed)  i. □ DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b)  6. ☑ Application Data Sheet. See 37 CFR 1.76  18. If a CONTINUING APPLICATION, check appropriate box, and sup or in an Application Data Sheet under 37 CFR 1.76: □ Gentinuation □ Divisional □ Continuation-in-part (CIP) Prior application information: Examiner □ Examiner			9. Assignment Papers (cover sheet & document(s))  10. 37 CFR 3.73(b) Statement Power of (when there is an assignee) Attorney  11. English Translation Document (if applicable)  12. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations  13. Preliminary Amendment  14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized)  15. Certified Copy of Priority Document(s) (if foreign priority is claimed)  16. Nonpublication request under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.  17. Other:  by the requisite information below and in a preliminary amendment, of prior application No.:/_  Group / Art Unit:					
For CONTINUATION OR DIVISIONAL APP  Box 5b, is considered a part of the disclosure of								
Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.								
19. CORRESPONDENCE ADDRESS								
Customer Number or Bar Code Label			or Correspondence address below					
Name								
Address								
City State Country, Telephone			Zip Code Fax					
Country		_		ra	<u> </u>			
,Name (Print/Type) Patrick A. Doody Registration No. (At			orney/Agent) 35,022					
Signature				Date	March 4, 2004	1		